Serotonin-Induced Hypersensitivity via Inhibition of Catechol O-Methyltransferase Activity

Molecular Pain

Volumn 8, Issue , 2012, Pages

  Tsao, Douglas ^a,b   Wieskopf, Jeffrey S ^c   Rashid, Naim ^b,d   Sorge, Robert E ^c   Redler, Rachel L ^e   Segall, Samantha K ^b   Mogil, Jeffrey S ^c   Maixner, William ^b   Dokholyan, Nikolay V ^b,e   Diatchenko, Luda ^b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d IL   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOL; CATECHOL METHYLTRANSFERASE; S ADENOSYLMETHIONINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BINDING SITE; BIOCHEMISTRY; CELL ASSAY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; FEMALE; HYPERSENSITIVITY; IN VIVO STUDY; MALE; MOUSE; NEUROMODULATION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN METHYLATION; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CATECHOL O-METHYLTRANSFERASE; FEMALE; MALE; MICE; PAIN THRESHOLD; PROTEIN BINDING; S-ADENOSYLMETHIONINE; SEROTONIN;

EID: 84859639031     PISSN: None     EISSN: 17448069     Source Type: Journal    
DOI: 10.1186/1744-8069-8-25     Document Type: Article

References (41)

1. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005, 14:135-143.
2. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W. Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 2007, 128:199-208. 10.1016/j.pain.2006.09.022, 1905861, 17084978.
3. Segall SK, Nackley AG, Diatchenko L, Lariviere WR, Lu X, Marron JS, Grabowski-Boase L, Walker JR, Slade G, Gauthier J, et al. Comt1 genotype and expression predicts anxiety and nociceptive sensitivity in inbred strains of mice. Genes Brain Behav 2010, 9:933-946. 10.1111/j.1601-183X.2010.00633.x, 2975805, 20659173.
4. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006, 314:1930-1933. 10.1126/science.1131262, 17185601.
5. Schul R, Frenk H. The role of serotonin in analgesia elicited by morphine in the periaqueductal gray matter (PAG). Brain Res 1991, 553:353-357. 10.1016/0006-8993(91)90849-Q, 1681985.
6. Roberts MH. 5-Hydroxytryptamine and antinociception. Neuropharmacology 1984, 23:1529-1536. 10.1016/0028-3908(84)90097-2, 6098854.
7. Taiwo YO, Levine JD. Serotonin is a directly-acting hyperalgesic agent in the rat. Neuroscience 1992, 48:485-490. 10.1016/0306-4522(92)90508-Y, 1534874.
8. Sufka KJ, Schomburg FM, Giordano J. Receptor mediation of 5-HT-induced inflammation and nociception in rats. Pharmacol Biochem Behav 1992, 41:53-56. 10.1016/0091-3057(92)90058-N, 1531705.
9. Lin SY, Chang WJ, Lin CS, Huang CY, Wang HF, Sun WH. Serotonin receptor 5-HT2B mediates serotonin-induced mechanical hyperalgesia. J Neurosci 2011, 31:1410-1418. 10.1523/JNEUROSCI.4682-10.2011, 21273425.
10. Tokunaga A, Saika M, Senba E. 5-HT2A receptor subtype is involved in the thermal hyperalgesic mechanism of serotonin in the periphery. Pain 1998, 76:349-355. 10.1016/S0304-3959(98)00066-9, 9718253.
11. Mannisto PT, Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 1999, 51:593-628.
12. Yin S, Biedermannova L, Vondrasek J, Dokholyan NV. MedusaScore: an accurate force field-based scoring function for virtual drug screening. J Chem Inf Model 2008, 48:1656-1662. 10.1021/ci8001167, 2665000, 18672869.
13. Ding F, Yin S, Dokholyan NV. Rapid flexible docking using a stochastic rotamer library of ligands. J Chem Inf Model 2010, 50:1623-1632. 10.1021/ci100218t, 2947618, 20712341.
14. Rutherford K, Le Trong I, Stenkamp RE, Parson WW. Crystal structures of human 108 V and 108 M catechol O-methyltransferase. J. Mol. Biol. 2008, 380:120-130. 10.1016/j.jmb.2008.04.040, 18486144.
15. Kopin IJ, Zukowska-Grojec Z, Bayorh MA, Goldstein DS. Estimation of intrasynaptic norepinephrine concentrations at vascular neuroeffector junctions in vivo. Naunyn Schmiedebergs Arch Pharmacol 1984, 325:298-305. 10.1007/BF00504372, 6728040.
16. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry 1999, 46:1219-1233. 10.1016/S0006-3223(99)00127-4, 10560027.
17. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, Taskinen J. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995, 34:4202-4210. 10.1021/bi00013a008, 7703232.
18. Garris PA, Ciolkowski EL, Pastore P, Wightman RM. Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 1994, 14:6084-6093.
19. Goldstein DS, Zimlichman R, Stull R, Keiser HR, Kopin IJ. Estimation of intrasynaptic norepinephrine concentrations in humans. Hypertension 1986, 8:471-475. 10.1161/01.HYP.8.6.471, 3710555.
20. Mogil JS, Crager SE. What should we be measuring in behavioral studies of chronic pain in animals?. Pain 2004, 112:12-15. 10.1016/j.pain.2004.09.028, 15494180.
21. Mogil JS. Animal models of pain: progress and challenges. Nat Rev Neurosci 2009, 10:283-294.
22. Greenspan JD, Slade GD, Bair E, Dubner R, Fillingim RB, Ohrbach R, Knott C, Mulkey F, Rothwell R, Maixner W. Pain sensitivity risk factors for chronic TMD: descriptive data and empirically identified domains from the OPPERA case control study. J Pain 2011, 12:T61-74. 10.1016/j.jpain.2011.08.006, 22074753.
23. Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 1958, 233:702-705.
24. Hoffman JL. Chromatographic analysis of the chiral and covalent instability of S-adenosyl-L-methionine. Biochemistry 1986, 25:4444-4449. 10.1021/bi00363a041, 3530324.
25. Borchardt RT, Wu Y. S-Aristeromycinyl-L-homocysteine, a Potent Inhibitor of S-Adenosylmethionine-Dependent Transmethylations. J. Med. Chem. 1976, 19:197-198. 10.1021/jm00223a043, 1246047.
26. Lin MT, Chandra A, Chi ML, Kau CL. Effects of increasing serotonergic receptor activity in brain on analgesic activity in rats. Exp Neurol 1980, 68:548-554. 10.1016/0014-4886(80)90108-9, 6966578.
27. Smith AJ. The analgesic effects of selective serotonin reuptake inhibitors. J Psychopharmacol 1998, 12:407-413. 10.1177/026988119801200413, 10065917.
28. Messing RB, Lytle LD. Serotonin-containing neurons: their possible role in pain and analgesia. Pain 1977, 4:1-21.
29. Lynch ME. Antidepressants as analgesics: a review of randomized controlled trials. J Psychiatry Neurosci 2001, 26:30-36. 1408040, 11212591.
30. Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des 2005, 11:2945-2960. 10.2174/1381612054864993, 16178755.
31. Mays TA. Antidepressants in the management of cancer pain. Curr Pain Headache Rep 2001, 5:227-236. 10.1007/s11916-001-0036-8, 11309210.
32. Wolfe F, Cathey MA, Hawley DJ. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994, 23:255-259. 10.3109/03009749409103725, 7973479.
33. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996, 39:1852-1859. 10.1002/art.1780391111, 8912507.
34. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002, 112:191-197. 10.1016/S0002-9343(01)01089-0, 11893345.
35. Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995, 61:445-449. 10.1016/0304-3959(94)00218-4, 7478688.
36. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50:2974-2984. 10.1002/art.20485, 15457467.
37. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136:432-444. 10.1016/j.pain.2008.02.024, 18395345.
38. Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. Expert Opin Pharmacother 2010, 11:2813-2825. 10.1517/14656566.2010.507192, 20642317.
39. Khare SD, Caplow M, Dokholyan NV. The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2004, 101:15094-15099. 10.1073/pnas.0406650101, 524068, 15475574.
40. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, Kolachana BS, Hyde TM, Herman MM, Apud J, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004, 75:807-821. 10.1086/425589, 1182110, 15457404.
41. Liang K, Zeger SL. Longitudinal data analysis using generalized linear models Biometrika 1986, 73:13-22.